Nurix Therapeutics' Chief Legal Officer, Christine Ring, reported the sale of 8,148 shares of the company's common stock on March 2, 2026, according to a Form 4 filed with the U.S. Securities and Exchange Commission. The shares were disposed of at a weighted average sales price of $15.4385, producing total proceeds of $125,792.
The execution price for the shares transacted in the sale ranged between $15.16 at the low end and $15.845 at the high end. The filing specifies that the disposition was completed under a pre-established Rule 10b5-1 trading arrangement. After the sale, Ring is recorded as directly owning 34,601 shares of Nurix Therapeutics.
The sale comes against a backdrop of notable recent share-price movement for the biotech. Nurix stock has rallied roughly 67% over the past six months but, at the same time, is down about 17% on a year-to-date basis. An analysis cited in company-related research suggests the equity may be undervalued at prevailing levels, and additional institutional research is available for subscribers seeking deeper valuation and growth detail.
Analyst reactions and updates
Following publication of Nurix's fiscal fourth-quarter 2025 results, several brokerage research teams adjusted their views and price targets. The company reported a net loss of $0.82 per share for the quarter, a result that was slightly better than the $0.84 per share loss estimated by one research firm, which led that firm to raise its price target to $32 and keep a Buy rating in place.
Other firms also moved their models and targets. Piper Sandler raised its price target to $35, referencing accelerated development plans for Nurix's bexobrutideg candidate in chronic lymphocytic leukemia and small lymphocytic lymphoma. Stifel likewise pushed its target to $35, noting that registrational trials planned for 2026 will be important for the bexobrutideg program.
RBC Capital increased its target to $30 while maintaining an Outperform rating, characterizing recent public updates as consistent with previously disclosed information. BTIG reiterated a Buy stance with a $30 price target, emphasizing Nurix's cash position and progress across critical programs. BTIG also highlighted a material trial design choice - a planned head-to-head comparison of bexdeg versus pirtobrutinib in a phase 3 confirmatory study - as a noteworthy strategic development.
What the filings and updates show
The Form 4 filing documents an insider sale executed per a Rule 10b5-1 plan, which indicates pre-arranged terms for disposition. The post-sale ownership figure shows Ring retains a meaningful equity stake. Separately, the string of analyst target increases and reiterated Buy/Outperform ratings reflect a consensus shift toward a more constructive view of Nurix's near-term development plans and program priorities announced with the fiscal Q4 2025 results.
Investors assessing exposure to the company can weigh the insider transaction alongside the updated analyst assumptions and planned registrational milestones in 2026 for the bexobrutideg program.